
The Australian competition regulator has approved the proposed acquisition of collaboration software firm Slack by CRM giant Salesforce for US$37 billion, stating the deal was unlikely to lessen competition.
The Australian Competition and Consumer Commission (ACCC) on Thursday, May 20, announced that it would not oppose the planned acquisition announced by Salesforce last December and is still awaiting US regulator approval.
The deal is the biggest in the CRM giant’s 21 year history and will see it compete with Microsoft in another market, with the companies already competing in sales, productivity and data visualisation software.
The ACCC considered the effect of the acquisition on the supply of CRM solutions and the supply of team collaboration software in Australia during a 50-day review that began in March.
“Salesforce and Slack mostly supply different software with distinct purposes, so there is minimal direct competitive overlap between them,” ACCC Chair Rod Sims said.
“We focused on whether Salesforce having both CRM and team collaboration solutions could give rise to a substantial lessening of competition.”
Mr Sims said most interested parties raised no concerns with the deal and if Salesforce did engage in anticompetitive bundling or foreclosure customers had several alternatives in the likes of Microsoft, Oracle, SAP, and Adobe. Microsoft’s Teams products also offers an alternative to the Slack software, he said.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas